Literature DB >> 22201041

Treating cardiac arrhythmias detected with an implantable cardiac monitor in patients after an acute myocardial infarction.

Christian Jons1, Poul Erik Bloch Thomsen.   

Abstract

OPINION STATEMENT: Using an implantable cardiac monitor (ICM) in patients with acute myocardial infarction (MI) allows continuous electrocardiogram monitoring and provides a much more detailed picture of the incidence of brady- and tachyarrhythmias than conventional follow-up. The CARISMA study was the first to use the ICM in post-MI patients with moderate to severe left ventricular systolic dysfunction. Atrial fibrillation (AF) events lasting longer than 30 s were associated with an almost threefold increase in the risk of major cardiac events. This confirms the current definition of clinically significant AF episodes, as patients with episodes of shorter duration were not at increased risk. The association of AF to progressive heart failure, reinfarction, and cardiovascular death underlines the need for an intensive follow-up of post-MI patients with new-onset AF in order to reveal underlying causes of AF such as progressive left ventricular dysfunction or myocardial ischemia. Asymptomatic, especially nightly, bradycardia episodes including high-degree 2°-3° atrioventricular (AV) block, sinus bradycardia, and sinus arrest were frequently documented by ICM in the CARISMA study. Ten percent of patients experienced high-degree 2°-3° AV block, of which the main part was nightly and asymptomatic, and 50% of all cardiovascular deaths occurred in this group, most from severe heart failure. Therefore, in post-MI patients with paroxysmal high-degree AV block, pacemaker implantation should be done, and in the case of left ventricular dysfunction (LVEF ≤ 35%), an implantable cardioverter defibrillator/cardiac resynchronization therapy defibrillator (ICD/CRT-D) may be indicated. Nonsustained ventricular tachycardia (VT) is very frequent in post-MI patients, and in the CARISMA study, high-risk patients with nonsustained VT were implanted with an ICD. Furthermore, in 10% of the patients, the ICM recorded nonsustained VT episodes of ≥ 16 beats per minute, resulting in a twofold increase in the risk for cardiac death. Thus, patients with nonsustained VT should undergo careful investigation, and we recommend a repeat echocardiography and electrophysiological stimulation in these patients. Patients with sustained VT or VF should receive an ICD.

Entities:  

Year:  2012        PMID: 22201041     DOI: 10.1007/s11936-011-0163-4

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  56 in total

1.  Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes.

Authors:  S S Rathore; A K Berger; K P Weinfurt; K A Schulman; W J Oetgen; B J Gersh; A J Solomon
Journal:  Circulation       Date:  2000-03-07       Impact factor: 29.690

2.  Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.

Authors:  Ilan Goldenberg; Arthur J Moss; Scott McNitt; Wojciech Zareba; W Jackson Hall; Mark L Andrews; David J Wilber; Helmut U Klein
Journal:  J Am Coll Cardiol       Date:  2006-04-17       Impact factor: 24.094

3.  Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases.

Authors:  A Bayés de Luna; P Coumel; J F Leclercq
Journal:  Am Heart J       Date:  1989-01       Impact factor: 4.749

4.  Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

Authors: 
Journal:  Am J Cardiol       Date:  1990-10-01       Impact factor: 2.778

5.  Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.

Authors:  Lars Køber; Karl Swedberg; John J V McMurray; Marc A Pfeffer; Eric J Velazquez; Rafael Diaz; Aldo P Maggioni; Viatcheslav Mareev; Grzegorz Opolski; Frans Van de Werf; Faiez Zannad; Georg Ertl; Scott D Solomon; Steven Zelenkofske; Jean-Lucien Rouleau; Jeffrey D Leimberger; Robert M Califf
Journal:  Eur J Heart Fail       Date:  2006-02-28       Impact factor: 15.534

6.  A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.

Authors:  U Elkayam; J Amin; A Mehra; J Vasquez; L Weber; S H Rahimtoola
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

7.  Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second danish verapamil infarction trial studies.

Authors:  R S Gibson; J F Hansen; F Messerli; K B Schechtman; W E Boden
Journal:  Am J Cardiol       Date:  2000-08-01       Impact factor: 2.778

8.  Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide.

Authors:  Henriette Sloth Pedersen; Hanne Elming; Marie Seibaek; Hans Burchardt; Bente Brendorp; Christian Torp-Pedersen; Lars Køber
Journal:  Am J Cardiol       Date:  2007-06-27       Impact factor: 2.778

Review 9.  Post-myocardial infarction beta-blocker therapy: the bradycardia conundrum. Rationale and design for the Pacemaker & beta-blocker therapy post-MI (PACE-MI) trial.

Authors:  Jeffrey J Goldberger; Robert O Bonow; Michael Cuffe; Alan Dyer; Philip Greenland; Yves Rosenberg; Robert O'Rourke; Prediman K Shah; Sidney Smith
Journal:  Am Heart J       Date:  2008-01-31       Impact factor: 4.749

10.  The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative.

Authors:  Sripal Bangalore; Franz H Messerli; Fang-Shu Ou; Jacqueline Tamis-Holland; Angela Palazzo; Matthew T Roe; Mun K Hong; Eric D Peterson
Journal:  Eur Heart J       Date:  2009-09-30       Impact factor: 29.983

View more
  2 in total

Review 1.  [Implantable loop recorder BioMonitor 2 (Biotronik)].

Authors:  Thorsten Lewalter; Clemens Jilek
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-11-15

2.  Global longitudinal strain predicts incident atrial fibrillation and stroke occurrence after acute myocardial infarction.

Authors:  Flemming Javier Olsen; Sune Pedersen; Jan Skov Jensen; Tor Biering-Sørensen
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.